You are here: Industry Insights > VLA1553

News List

Positive Phase III results for Valneva’s chikungunya vaccine pharmatimes
August 06, 2021
Valneva’s single-shot chikungunya vaccine candidate, VLA1553, has seen positive topline results from its Phase III pivotal trial. VLA1553 was recently awarded breakthrough designation status by the Food and Drug Administration (FDA).
Valneva’s chikungunya virus vaccine granted breakthrough designation pharmatimes
July 12, 2021
French speciality vaccine company Valneva has announced that its single-shot chikungunya vaccine candidate has received a breakthrough therapy designation from the US Food and Drug Administration (FDA).
Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases firstwordpharma
July 06, 2021
ValnevaSE announced today it will host a virtual symposium titled, "Developing new vaccines to protect against infectious diseases at home and abroad" on July 9, at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID）
Valneva’s Chikungunya Vax Granted PRIME Designation contractpharma
October 22, 2020
Becomes the first company worldwide to advance a chikungunya vaccine candidate into Phase III.